IL17A and neoplasm: Binding of IL-6, IL-10, and IL-17 to their receptors promotes the activation of JAKs [48, 49]; however, the anti-tumor immunomodulatory role of IL-6, IL-10 and IL-17 remains unclear and appears contradictory in some aspects.